Unlocking the Potential of Cannabinoid Medicines

Company Highlights
InMed is a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary platform technologies to develop novel therapeutics for the treatment of diseases with high unmet medical needs.

Cannabinoids
Beyond the two most well-known cannabinoids THC and CBD, the human body’s endocannabinoid receptors are predisposed to interact with more than 100 other cannabinoids that have potential therapeutic properties. Many of these cannabinoids have been neglected as targets of scientific research because they are found in extremely low concentrations in the cannabis plant.

InMed is developing novel, non-THC, topically applied cannabinoid-based treatments of diseases with high unmet medical needs.

Biosynthesis
Proprietary biosynthesis program will allow InMed, and potentially other companies, through commercial partnerships, to access cannabinoids that are found in very limited amounts in the plant. These cannabinoids (i.e. “minor cannabinoids”) may hold significant potential to treat human diseases.

This potentially industry-disruptive cannabinoid manufacturing process may offer several advantages over traditional methods (extraction from plants and chemical synthesis), which include:
- Significant cost & time savings vs existing growing / harvesting / extraction / purification methods
- Access to minor cannabinoids that are currently economically unfeasible via plant extraction
- Enhanced production, purification and quality control vs naturally-sourced products
- Increased structural integrity vs chemical manufacturing methods

Clinical Pipeline

<table>
<thead>
<tr>
<th>Therapeutic Area</th>
<th>INM-755</th>
<th>INM-085</th>
<th>INM-405</th>
</tr>
</thead>
<tbody>
<tr>
<td>Epidermolysis Bullosa</td>
<td>Glaucoma</td>
<td>Orofacial Pain</td>
<td></td>
</tr>
<tr>
<td>Addressable Market</td>
<td>$1.0B</td>
<td>$5.6B</td>
<td>$4.0B</td>
</tr>
<tr>
<td>Market Potential</td>
<td>$10.1K</td>
<td>$14.2M</td>
<td>$52.7M</td>
</tr>
</tbody>
</table>
**Strong Intellectual Property Strategy**

Filed several Patent Cooperation Treaty (PCT) and provisional patent applications to protect our inventions. Recent PCT patent applications include:

- **Mar. 18, 2019:** Biosynthesis technology for the manufacturing of pharmaceutical-grade cannabinoids
- **Sept. 25, 2018:** INM-405 program and other unique compositions as cannabinoid-based topical therapies for the treatment of pain
- **Sept. 10, 2018:** Proprietary biosynthesis program for the manufacture of cannabinoids that are identical to those found in nature
- **May 14, 2018:** INM-085, a cannabinoid-based topical therapy for glaucoma
- **May 4, 2017:** Cannabinoid-based topical therapy for diseases and conditions associated with Intermediate Filament Dysfunction

**INM-755 Epidermolysis Bullosa (“EB”)**

- Group of genetic conditions causing skin to be very fragile and blister / rupture easily in response to minor injury or friction, such as rubbing or scratching
- INM-755 being investigated to deliver symptomatic relief in all EB patients via multiple potential mechanisms:
  - accelerated wound healing
  - pain reduction
  - itch reduction
  - reduce inflammation
  - antimicrobial activity
- May re-establish the epidermal / dermal junction by upregulation of specific keratins in the skin, potentially reversing the disease in a subset of EB patients

**INM-085 Glaucoma**

- Reduces the intraocular pressure (IOP) in the affected eyes
- Provide neuroprotection for the retinal ganglion cells (RGCs) and other optic nerve tissues in the affected eyes
- INM-085 utilizes a 1x per day hydrogel to improve compliance
- Preclinical animal data showed enhanced penetration of cannabinoid molecules through the cornea and lens compared to control

**Development Targets**

<table>
<thead>
<tr>
<th>1Q19</th>
<th>2H19</th>
<th>2H20</th>
<th>2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>✓ Finalized formulation for INM-755</td>
<td>Submit Clinical Trial Application to Health Canada</td>
<td>Initiate Phase 1 clinical trial in Canada</td>
<td>Initiate Phase 1/2a in EB patients</td>
</tr>
</tbody>
</table>

**Management Team**

**Eric A. Adams, MIBS**
Chief Executive Officer
25+ years experience in global biopharma leadership, business development, sales, marketing, M&A with enGene, QLT, Abbott, Fresenius.

**Jeff Charpentier, CPA, CA**
Chief Financial Officer
25+ years financial experience in biotech and tech companies, including Lifebank Corp., Inex Pharmaceuticals, and Chromos Molecular Systems.

**Alexandra D.J. Mancini, MSc**
SVP, Clinical and Regulatory Affairs
30+ years experience in global biopharmaceutical R&D with numerous biotech companies, including Sirius Genomics, INMEX Pharmaceuticals, and QLT.

**Dr. Eric C. Hsu, PhD**
VP, Preclinical R&D
18+ years scientific leadership experience with enGene Inc. in novel gene transfer technologies, formulation development and process development.

**Josh Blacher, MBA**
Chief Business Officer
20+ years senior leadership, capital markets experience with Therapix, Galmed, Teva; investment banking with Morgan Stanley, and Lehman Bros.

**Michael Woudenberg, P.Eng.**
VP, Chemistry, Manufacturing & Controls
20+ years experience in engineering, leadership and GMP manufacturing and scale up at 3M, Cardiome Pharma, Arbutus Biopharma, and Phyton Biotech.

**Investor Relations Contacts**

<table>
<thead>
<tr>
<th>Name</th>
<th>Email</th>
</tr>
</thead>
<tbody>
<tr>
<td>Josh Blacher</td>
<td><a href="mailto:jblacher@inmedpharma.com">jblacher@inmedpharma.com</a></td>
</tr>
<tr>
<td>Joe Green</td>
<td><a href="mailto:jgreen@edisongroup.com">jgreen@edisongroup.com</a></td>
</tr>
</tbody>
</table>